Recommended Free Tools
In the United States, the FDA-approved CRISPR gene therapy Casgevy is for specific patients with sickle cell disease or transfusion-dependent beta-thalassemia—not for genetic disorders in general. It edits a patient’s own blood stem cells outside the body, but treatment also involves intensive chemotherapy, stem-cell collection and reinfusion, and long-term safety monitoring. Results in clinical trials have been encouraging, though they do not establish a permanent cure or settle every long-term risk.
What CRISPR gene therapy means
CRISPR is a gene-editing method: it can be directed to alter DNA at a chosen site. In Casgevy, the FDA-approved CRISPR/Cas9 therapy discussed here, the editing is done ex vivo—outside the body—in a patient’s own blood-forming stem cells. The edited cells are then infused back into that patient.
This differs from in vivo editing, in which a gene-editing treatment is delivered into the body to act on cells there. It also differs from gene addition, which supplies genetic material rather than using CRISPR to edit a target in the patient’s cells.
What Casgevy changes
Casgevy is designed to increase fetal hemoglobin (HbF), a form of hemoglobin that can help red blood cells function without sickling in sickle cell disease and increase total hemoglobin in beta-thalassemia. It does not repair every disease-causing variant throughout the body. Its strategy is to change the blood-cell population that develops from the edited stem cells.
#1 Best Overall
Who can receive FDA-approved CRISPR therapy in the United States?
As of October 4, 2026, the FDA lists Casgevy for patients aged 2 years and older with either sickle cell disease (SCD) and recurrent vaso-occlusive crises (VOCs), or transfusion-dependent beta-thalassemia (TDT). A VOC is a painful crisis caused by sickled red blood cells obstructing blood flow. TDT is beta-thalassemia severe enough that a person depends on regular blood transfusions.
The FDA expanded Casgevy’s labeled age to 2 years and older for both indications on July 1, 2026. The younger-age expansion relied on product characteristics, clinical study evidence in older children, and extrapolation; the existence of an indication down to age 2 does not mean the same amount of direct trial evidence is available for every age within the label.
FDA approval applies to the specified conditions and populations. It does not mean CRISPR is an approved treatment for other genetic diseases, or that every experimental gene-editing product is approved. In the United States, human clinical studies of gene therapy require an investigational new drug application, and marketing requires an approved biologics license application.
What treatment involves
Although Casgevy is described as a one-time infusion, that phrase refers to the cell infusion—not to a simple visit or a treatment without preparation. The therapy requires a substantial clinical process.
Free tools Windows power users keep installed
One-click scans. No signup required.
- Collect the patient’s blood stem cells. These cells are taken from the person who will receive treatment; Casgevy is autologous, so it does not use a donor’s stem cells.
- Edit the cells outside the body. The collected cells are processed and edited with CRISPR/Cas9 to support increased HbF production.
- Give myeloablative conditioning chemotherapy. This intensive chemotherapy clears space in the bone marrow for the edited cells. “Myeloablative” means it strongly suppresses or destroys the marrow’s existing blood-forming cells.
- Infuse the edited cells and monitor recovery. The cells are returned to the patient and must engraft—settle and begin producing blood cells—in the bone marrow. Hospitalization and recovery are part of the treatment pathway.
This is transplant-like in that cells are infused after marrow-clearing chemotherapy, but it is not a donor stem-cell transplant: the cells come from the patient. The conditioning regimen and engraftment period are important parts of the treatment burden, separate from the editing itself.
What benefits have clinical studies shown?
FDA’s 2023 summary of the pivotal SCD evidence described an ongoing, multicenter, single-arm trial. Of 44 patients who received Casgevy, 29 of the 31 with sufficient follow-up for evaluation—93.5%—had no severe VOCs for at least 12 consecutive months during the 24-month follow-up period. That is an evaluable subgroup result, not 29 of all 44 treated patients. The endpoint shows sustained freedom from severe crises during a defined window; it does not establish that recipients will never have symptoms again.
In FDA’s July 2026 summary of patients aged 5 to under 12, all 8 of 8 efficacy-evaluable SCD patients achieved the defined outcome of at least 12 months without severe VOCs. In the TDT group, 8 of 9 efficacy-evaluable patients achieved transfusion independence for 12 consecutive months; the reported median duration of transfusion independence was 20.1 months. These small groups and their specific endpoints matter when interpreting the figures.
For people who meet the studied criteria, fewer severe crises or a period without transfusions can represent a major benefit. But these trial findings are not a randomized comparison with another therapy, and they do not show that every treated person will have the same outcome.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallWhat are the risks and limits?
Conditioning and treatment complications
The chemotherapy needed before infusion is intensive and is a major risk and burden in its own right. In its 2026 notice, the FDA listed mucositis and febrile neutropenia among the most common adverse reactions in SCD and TDT patients; decreased appetite was also listed for SCD. Mucositis is inflammation and soreness of the lining of the mouth or digestive tract. Febrile neutropenia is fever with a dangerously low level of infection-fighting neutrophils.
FDA label warnings include neutrophil engraftment failure, delayed platelet engraftment, hypersensitivity reactions, and off-target genome-editing risk. Off-target editing means an unintended DNA change outside the intended target site. These are risks to discuss with the treating specialist, alongside the potential benefit and the individual’s health and treatment history.
Long-term safety remains under study
In its July 2026 approval letter, FDA required a prospective, multicenter postmarketing study involving 250 people with SCD and 150 with TDT, with 15 years of follow-up for each enrolled participant. The study is intended to characterize secondary malignancy, off-target editing, and other long-term safety risks. FDA said spontaneous adverse-event reports are not sufficient to assess these risks.
This requirement reflects an unresolved need for long-term evidence; it is not proof that Casgevy causes cancer. More generally, FDA’s January 2020 gene-therapy guidance notes that lasting or long-acting changes can make delayed adverse events relevant and may warrant extended follow-up. FDA issued draft genome-editing safety guidance in April 2026 on using next-generation sequencing to assess off-target editing and loss of genome integrity. That document is draft guidance, not a final rule.
Best Value
Why “one-time treatment” does not mean “proven cure”
The infusion is a single dose, but the evidence so far measures outcomes over defined follow-up periods, not across a recipient’s entire lifetime. Many participants in the studied groups achieved the specified crisis-free or transfusion-independent endpoint, but those results do not prove a permanent cure for every recipient. “Potentially transformative” is more accurate than calling Casgevy a universal or established permanent cure.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How CRISPR therapy differs from another FDA-approved SCD gene therapy
Casgevy is not the only gene therapy FDA has approved for SCD. The FDA’s 2023 announcement also described Lyfgenia, a lentiviral gene-addition therapy rather than a CRISPR product. The therapies’ trial results use different endpoints and study windows, so their reported percentages should not be treated as a head-to-head comparison.
| Feature | Casgevy | Lyfgenia |
|---|---|---|
| Approach | CRISPR/Cas9 edits a patient’s own blood stem cells ex vivo to increase HbF. | Lentiviral gene therapy adds a gene-therapy-derived hemoglobin to a patient’s blood stem cells. |
| FDA SCD population described in the cited approval information | As of July 1, 2026, patients aged 2 years and older with SCD and recurrent VOCs. | FDA’s 2023 approval announcement described patients aged 12 and older with a history of vaso-occlusive events. |
| Reported trial endpoint and result | FDA’s 2023 summary: 29 of 31 evaluable participants (93.5%) had no severe VOCs for at least 12 consecutive months within the 24-month follow-up period. | FDA’s 2023 summary: 28 of 32 trial participants achieved complete resolution of VOEs during the specified 6-to-18-month assessment window. |
| Safety monitoring noted in the cited FDA information | FDA required a postmarketing study of 250 SCD and 150 TDT recipients, with 15 years of follow-up per participant, to study secondary malignancy, off-target editing, and long-term safety. | FDA’s 2023 announcement noted a boxed warning for hematologic malignancy and lifelong malignancy monitoring. |
The table reflects separate FDA summaries, different endpoint definitions, and different follow-up windows; it cannot establish which therapy is better for an individual. A treatment decision also depends on the patient’s eligibility and circumstances, and should be made with clinicians experienced in these therapies.
How to avoid unsafe or unapproved gene-therapy claims
Gene editing is a regulated medical intervention, not a home experiment. FDA warns that do-it-yourself gene-therapy kits are unsafe and that their sale is unlawful. Do not try to self-administer a gene therapy or bypass clinical oversight.
Quick Recap
- Check whether the treatment is FDA-approved for the specific condition and patient group being discussed; approval for one indication does not establish approval for another.
- If a treatment is experimental, ask whether it is being studied under appropriate regulatory oversight, rather than relying on claims in an advertisement or online post.
- Ask the treating specialist to explain the intended benefit, conditioning and recovery, known warnings, evidence for the patient’s age group, and required follow-up.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
